CRISPR-Engineered immune cells take on stomach and colon cancers
NCT ID NCT04426669
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested a new approach for people with advanced gastrointestinal cancers that had stopped responding to standard treatments. Doctors removed immune cells from patients' tumors, used CRISPR gene editing to disable a gene called CISH, and then infused the modified cells back into the patient along with chemotherapy. The goal was to see if this treatment was safe and could shrink tumors. The study involved 23 participants and has been completed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Genetically-engineered tumor-infiltrating lymphocytes (TIL) with CISH gene knockout using CRISPR/Cas9, plus chemotherapy drugs cyclophosphamide and fludarabine
- What this could lead to
- If successful, this approach could offer a new treatment option for patients with advanced gastrointestinal cancers that have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with only 23 participants, so results may not apply to all patients. The treatment involves intensive chemotherapy and gene editing, which carries risks of side effects and uncertain long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF GASTROINTESTINAL TRACT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients